| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
IC50: larger than 500 μM (GABA transaminase)[1]
L-DABA hydrobromide targets GABA transaminase, the enzyme responsible for the degradation of GABA. By inhibiting GABA transaminase, the compound increases GABA levels in the brain. GABA is the chief inhibitory neurotransmitter in the central nervous system. L-DABA hydrobromide also exhibits antitumor activity, suggesting additional targets involved in cancer cell proliferation. |
|---|---|
| ln Vitro |
An incubation period of 24 hours at 37°C with 10 mM L-2,4-Diaminobutyric acid completely destroys the tumor cells. The osmotic lysis that results from the non-saturated intracellular buildup of L-DABA hydrobromide is most likely the cause of the cell-destructive action of L-DABA hydrobromide. L-alanine and L-methionine could be incubated together concurrently to eliminate the negative effects of L-DABA hydrobromide[1]. L-DABA hydrobromide is a non-linear, non-competitive inhibitor of GABA transaminase activity, according to kinetic studies. GABA levels are raised in response to L-DABA hydrobromide, which also inhibits GABA transaminase activity[2]. An amino acid analogue called L-2,4-Diaminobutyric acid exhibits cytolytic effects on the human glioma cell line SKMG-1 as well as normal human fibroblasts. After a 24-hour incubation at 37°C, the doses of L-DABA hydrobromide required to lower the cell count to 50% of control are 12.5 mM for human fibroblasts and 20 mM for the glioma cell line[3].
L-DABA hydrobromide demonstrates weak in vitro inhibition of GABA transaminase with an IC50 of greater than 500 μM. It is a non-linear, non-competitive inhibitor of GABA transaminase activity. The compound exhibits antitumor activity in vitro. |
| ln Vivo |
The development of tumors is reduced by 43.4% when treated with L-DABA hydrobromide[1]. In vivo GABA transaminase inhibition is more potent than in vitro inhibition when using L-DABA hydrobromide[2].
L-DABA hydrobromide exhibits antitumor activity in vivo. Its inhibition of GABA transaminase raises GABA levels in the brain. The compound has been studied for its anticonvulsant activity and for the treatment of neurological disorders. Further in vivo studies are needed to fully characterize its therapeutic potential. |
| Enzyme Assay |
The in vitro enzyme assay for L-DABA hydrobromide involves measuring its inhibition of GABA transaminase activity. Recombinant GABA transaminase is incubated with GABA as a substrate. The production of succinic semialdehyde is monitored. L-DABA hydrobromide is incubated with the enzyme and substrate at various concentrations. The IC50 value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for L-DABA hydrobromide typically use cancer cell lines to assess its antitumor activity. Cells are treated with the compound at various concentrations. Cell viability is measured using standard assays such as MTT or CellTiter-Glo. The compound's ability to inhibit cell proliferation is quantified.
|
| Animal Protocol |
In vivo animal experiments for L-DABA hydrobromide would typically use animal models of cancer or neurological disorders. The compound would be administered via intraperitoneal or oral routes. Tumor growth, GABA levels, and neurological outcomes would be assessed. Further studies are needed to characterize its in vivo activity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of L-DABA hydrobromide are not extensively documented. As a small molecule with a molecular weight of 199.05, the compound is expected to have reasonable bioavailability. Its amino acid-like structure may influence its absorption, distribution, metabolism, and excretion. Further pharmacokinetic studies are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for L-DABA hydrobromide are not extensively available in the public domain. As a research compound, it has not undergone extensive toxicological evaluation. Standard cytotoxicity assays in cancer cell lines may have been performed to assess safety margins. Further preclinical toxicology studies would be required before clinical development.
|
| References | |
| Additional Infomation |
L-DABA hydrobromide (L-2,4-Diaminobutyric acid hydrobromide) is a weak GABA transaminase inhibitor with an IC50 of greater than 500 μM. It exhibits antitumor activity in vivo and in vitro. The compound has a molecular weight of 199.05. No clinical trials or regulatory approvals have been reported.
|
| Molecular Formula |
C4H11BRN2O2
|
|---|---|
| Molecular Weight |
199.05
|
| Exact Mass |
198
|
| CAS # |
73143-97-2
|
| PubChem CID |
46735201
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.105
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
84.1
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(CN)[C@@H](C(=O)O)N.Br
|
| InChi Key |
RVCHWEZQMFNGBK-DFWYDOINSA-N
|
| InChi Code |
InChI=1S/C4H10N2O2.BrH/c5-2-1-3(6)4(7)8;/h3H,1-2,5-6H2,(H,7,8);1H/t3-;/m0./s1
|
| Chemical Name |
(2S)-2,4-diaminobutanoic acid;hydrobromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0239 mL | 25.1193 mL | 50.2386 mL | |
| 5 mM | 1.0048 mL | 5.0239 mL | 10.0477 mL | |
| 10 mM | 0.5024 mL | 2.5119 mL | 5.0239 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
